BMS-CA071-1000-RECHARGE
Phase III
OPEN TO ACCRUAL
A Phase 3, Two-Part, Randomized, Open-Label, Adaptive Study Comparing BMS-986365 Versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
REGENERON-R4336-ONC-20104
Phase I/II
OPEN TO ACCRUAL
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer